Showing papers by "Nan Lin published in 2006"
TL;DR: None of the biomarkers was predictive of treatment response in women with metastatic breast cancer; however, survival differed according to hormone receptor and p53 status.
Abstract: The response to paclitaxel varies widely in metastatic breast cancer. We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status. Among 474 women randomly assigned to paclitaxel at a dose of 175, 210, or 250 mg/m2, adequate primary tumor tissue was available from 175. Immunohistochemistry with two antibodies and fluorescence in situ hybridization were performed to evaluate HER2 status; p53 status was determined by immunohistochemistry and sequencing. Hormone receptor status was obtained from pathology reports. Objective response rate was not associated with HER2 or p53 status. There was a trend toward a shorter median time to treatment failure among women with HER2-positive tumors (2.3 versus 4.2 months; P = 0.067). HER2 status was not related to overall survival (OS). Hormone receptor expression was not associated with differences in response but was associated with longer OS (P = 0.003). In contrast, women with p53 over-expression had significantly shorter OS than those without p53 over-expression (11.5 versus 14.4 months; P = 0.002). In addition, triple negative tumors were more frequent in African-American than in Caucasian patients, and were associated with a significant reduction in OS (8.7 versus 12.9 months; P = 0.008). None of the biomarkers was predictive of treatment response in women with metastatic breast cancer; however, survival differed according to hormone receptor and p53 status. Triple negative tumors were more frequent in African-American patients and were associated with a shorter survival.
153 citations
TL;DR: Although the study failed to demonstrate the hypothesized level of activity as assessed by RECIST, there is sufficient evidence of clinical effect, albeit preliminary, to suggest that lapatinib can penetrate the CNS.
Abstract: 503 Background: One-third of women with HER2+ metastatic breast cancer develop central nervous system (CNS) metastases. This study evaluated the safety and efficacy of lapatinib, an oral inhibitor ...
116 citations
01 Oct 2006
TL;DR: In this preliminary study of 16 patients undergoing treatment for metastatic breast cancer, it is concluded that vessel shape may predict tumor response several months in advance of traditional methods.
Abstract: No current non-invasive method is capable of assessing the efficacy of brain tumor therapy early during treatment We outline an approach that evaluates tumor activity via statistical analysis of vessel shape using vessels segmented from MRA This report is the first to describe the changes in vessel shape that occur during treatment of metastatic brain tumors as assessed by sequential MRA In this preliminary study of 16 patients undergoing treatment for metastatic breast cancer we conclude that vessel shape may predict tumor response several months in advance of traditional methods
21 citations
TL;DR: In this article, the authors proposed an approximate minimum Hellinger distance estimator by adapting the approach to grouped data from a continuous distri bution, which is easier to compute the approximate version for either the continuous data or the grouped data.
Abstract: SUMMARY The minimum Hellinger distance estimator is known to have desirable properties in terms of robustness and efficiency. We propose an approximate minimum Hellinger distance estimator by adapting the approach to grouped data from a continuous distri bution. It is easier to compute the approximate version for either the continuous data or the grouped data. Given certain conditions on the model distribution and reason able grouping rules, the approximate minimum Hellinger distance estimator is shown to be consistent and asymptotically normal. Furthermore, it is robust and can be asymptotically as efficient as the maximum likelihood estimator. The merit of the estimator is demonstrated through simulation studies and real data examples.
10 citations